■ ELT Sight announced that in the largest published study to date on excimer laser trabeculostomy (ELT), an implant-free outpatient microinvasive glaucoma surgery, the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the Trabectome plus cataract surgery. The 245-patient study was published online in the journal International Ophthalmology.

Patients in the retrospective, nonrandomized, comparative, single surgery center study underwent 1 of 3 procedures: ELT plus cataract surgery, trabeculectomy with the Trabectome device plus cataract surgery, or cataract surgery alone. At 1-year postoperatively, ELT plus cataract surgery significantly reduced IOP and medication use.

In related news, ELT Sight has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. MLase manufactures and markets innovative laser systems, including the ExTra ELT laser and disposable applicator. The system received European Conformity (CE) certification in 2014 and is currently available in Europe. ELT Sight plans to initiate clinical studies in the United States this year.